Entrada Therapeutics, Inc. (TRDA)
5.25
+0.56
(+11.94%)
USD |
NASDAQ |
Nov 10, 16:00
5.255
0.00 (0.00%)
After-Hours: 20:00
Entrada Therapeutics Gross Profit Margin (Quarterly) : 22.65% for Sept. 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 22.65% |
| June 30, 2026 | 10.91% |
| March 31, 2026 | 8.00% |
| December 31, 2025 | 31.79% |
| September 30, 2025 | 25.65% |
| June 30, 2025 | 43.59% |
| March 31, 2025 | 95.40% |
| December 31, 2024 | 97.35% |
| Date | Value |
|---|---|
| September 30, 2024 | 95.40% |
| June 30, 2024 | 99.05% |
| March 31, 2024 | 98.42% |
| December 31, 2023 | 98.24% |
| September 30, 2023 | 98.17% |
| June 30, 2023 | 96.15% |
| March 31, 2023 | 97.86% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Prime Medicine, Inc. | -54.68% |
| Arrowhead Pharmaceuticals, Inc. | 91.15% |
| Oncolytics Biotech, Inc. | -- |
| Sangamo Therapeutics, Inc. | 39.18% |
| Sarepta Therapeutics, Inc. | 49.02% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -59.80% |
| Return on Assets | -47.70% |
| Return on Invested Capital | -50.48% |
| Profit Margin (Quarterly) | -4.39K% |
| Operating Margin (Quarterly) | -4.61K% |
| Return on Net Operating Assets | -243.3% |